Core Insights - Bavarian Nordic A/S has secured a contract valued over DKK 200 million to supply its MVA-BN smallpox/mpox vaccine to a European country, enhancing national preparedness against biological threats [1][2] - The total value of secured contracts in the Public Preparedness business has now exceeded DKK 3,000 million, aligning with the company's targeted guidance for 2025 [2][5] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in multiple countries, originally developed for smallpox vaccination [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, particularly in the area of mpox and smallpox [4] - The company aims to enhance public health preparedness and has a strong portfolio of travel vaccines [4] Financial Performance - The company maintains its revenue guidance for 2025 at DKK 5,700-6,700 million, with an EBITDA margin projected between 26-30% [2]

Core Points - Bavarian Nordic A/S has initiated two clinical trials for the MVA-BN mpox/smallpox vaccine targeting vulnerable populations, specifically infants under 2 years and pregnant or breastfeeding women [1][2] - The first study involves 344 infants aged 4-24 months, while the second study aims to enroll 359 women [1][2] - Both studies are conducted in the Democratic Republic of Congo, the epicenter of the ongoing mpox outbreak [1] - Bavarian Nordic is also sponsoring a trial for children aged 2-11 years, with topline results expected in Q3 2025 [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines and is a preferred supplier of mpox and smallpox vaccines to governments [5] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in several countries, including the U.S., Canada, and the EU [4] - The vaccine was originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure supply for the entire population, including immunocompromised individuals [4]